section name header

Indications ⬇

High Alert


Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Noted for patients receiving heparin and aspirin in addition to eptifibatide.

Interactions ⬆ ⬇

Drug-drug:

Drug-Natural Products:

Availability ⬆ ⬇

(Generic available)

Route/Dosage ⬆ ⬇

Acute Coronary Syndrome

Renal Impairment

Percutaneous Coronary Intervention

Renal Impairment

US Brand Names ⬆ ⬇

Integrilin

Action ⬆ ⬇

  • Decreases platelet aggregation by reversibly antagonizing the binding of fibrinogen to the glycoprotein IIb/IIIa binding site on platelet surfaces.
Therapeutic effects:
  • Reduction in risk of death or new MI in patients with acute coronary syndrome.
  • Reduction in risk of death, new MI, or need for urgent intervention in patients undergoing PCI.

Classifications ⬆ ⬇

Therapeutic Classification: antiplatelet agents

Pharmacologic Classification: glycoprotein iib iiia inhibitors

Pharmacokinetics ⬆ ⬇

Absorption: IV administration results in complete bioavailability.

Distribution: Unknown.

Metabolism/Excretion: 50% excreted by the kidneys.

Half-Life: 2.5 hr.

Time/Action Profile ⬆ ⬇

(effects on platelet function)

ROUTEONSETPEAKDURATION
IVimmediatefollowing bolusbrief‡

‡Inhibition is reversible following cessation of infusion.

Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆ ⬇

ep-ti-FIB-a-tide

Code ⬆

NDC Code